Retrospective Cohort Study on the Impact of PDL Treatment History on the Efficacy of HMME-PDT in Treating PWS Children
Launched by SECOND AFFILIATED HOSPITAL OF XI'AN JIAOTONG UNIVERSITY · Mar 9, 2025
Trial Information
Current as of April 29, 2025
Completed
Keywords
ClinConnect Summary
Background Hemoporfin-mediated photodynamic therapy (Hemoporfin-PDT) is considered a safe and effective treatment for port-wine stains (PWS). This study aims to investigate the influence of prior pulse dye laser (PDL) treatments history on the effectiveness of Hemoporfin-PDT in young children aged 1-3 years with PWS.
Methods Data was gathered for individuals with PWS aged 1-3 years who received two or more Hemoporfin-PDT treatments. The study population was stratified into two groups: Cohort 1 (No PDL) comprised patients without a history of PDL treatment, while Cohort 2 (Prior PDL) consis...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients clinically diagnosed with PWS (Port Wine Stain) who were between 1 and 3 years old at the time of their first HMME-PDT treatment.
- • Patients who, after evaluation by a clinician, are deemed eligible for HMME-PDT treatment and whose guardians have signed an informed consent form.
- • Patients who have undergone two or more HMME-PDT treatments.
- • ④ Patients with complete basic information and treatment-related information.
- Exclusion Criteria:
- • Exclusion of patients with syndromes associated with PWS.
- • Exclusion of patients with a history of treatments for PWS other than PDL treatment.
- • Patients with other vascular malformations. ④ Exclusion of patients who have received any other PWS treatment within 2 months prior to HMME-PDT treatment.
About Second Affiliated Hospital Of Xi'an Jiaotong University
The Second Affiliated Hospital of Xi'an Jiaotong University is a leading medical institution in China, dedicated to advancing healthcare through innovative clinical research and patient care. Affiliated with one of the country's premier universities, the hospital combines clinical excellence with academic rigor, fostering a multidisciplinary approach to healthcare challenges. With a strong emphasis on patient-centered care, the hospital engages in a wide range of clinical trials aimed at improving treatment outcomes and enhancing medical knowledge. Its commitment to ethical standards and regulatory compliance ensures that all research initiatives prioritize patient safety and scientific integrity.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Xi'an, Shaanxi, China
Patients applied
Trial Officials
Weihui Zeng
Study Chair
Second Affiliated Hospital of Xi'an Jiaotong University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported